Analysis of Immunological Response and QOL with adoptive transfer of T cells in cancer patients
| Project/Area Number |
15590606
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
General internal medicine (including Psychosomatic medicine)
|
|---|
| Research Institution | International Medical Centre of Japan |
|---|
Principal Investigator |
ARUGA Etsuko International Medical Center of Japan, Division of Gastrointestinal Diseases, Research Fellow, 消火器疾患研究部, 研究員 (20343551)
|
|---|
| Project Period (FY) |
2003 – 2006
|
| Project Status |
Completed (Fiscal Year 2006)
|
| Budget Amount *help |
¥3,200,000 (Direct Cost: ¥3,200,000)
Fiscal Year 2006: ¥600,000 (Direct Cost: ¥600,000)
Fiscal Year 2005: ¥600,000 (Direct Cost: ¥600,000)
Fiscal Year 2004: ¥1,000,000 (Direct Cost: ¥1,000,000)
Fiscal Year 2003: ¥1,000,000 (Direct Cost: ¥1,000,000)
|
|---|
| Keywords | FACT-BRM / QOL / activated T cells / cancer immunotherapy / palliative care / cytokine |
|---|
| Research Abstract |
Quality of life (QOL) in cancer patients is often lower because of the influence of Type 2 cytokine or decrease of the lymphocyte. To assess QOL in cancer patients who received the activated T cell transfer, the Japanese version of the Functional Assessment of Cancer Therapy-Biological Response Modifier (FACT-BRM) was developed through an iterative forward-backward translation sequence used throughout the FACIT Translation Project Procedures and Guidelines. The Pilot testing of the Japanese version of FACT-BRM was done and questionnaire items were found easy to understand, and none were irrelevant or offensive. After the analysis of the results of the pilot study, the Japanese version of the FACT-BRM was finalized. The FACT-BRM-TOI (trial outcome index) was used to assess QOL in 62 cancer patients who received the activated T cell transfer. In 25 of 62 (40%) patients, QOL scores increased after the activated T cell transfer. In the patients, CD8P+CD28+ T cells and CD3+CXCR3+ T cells increased in their numbers after the T cell transfer. Therefore, the activated T cell transfer could improve QOL in cancer patients due to increase the number of Type 1 T cells in vivo. Further experiments are needed to verify the effectiveness of the activated T cell transfer to improve QOL in cancer patients to compare with that of the patients who do not receive the activated T cell transfer in the same background.
|
Report
(5 results)
Research Products
(1 results)
